IDH2 and central nervous system cancer: IDH mutations are prevalent in several rare malignancies, such as iCCA, glioma, acute myeloid leukemia, chondrosarcoma, thyroid carcinoma, angioimmunoblastic T-cell lymphoma, and other cancers [31,32,33,34,35,36].